









Markets
/
Stocks
/
nasdaq-elut
/

Elutia Inc

ELUT

1.090USD

+0.010+0.93%

Close 09/19, 16:00（ET）Quotes delayed by 15 min

46.21MMarket Cap

LossP/E TTM



Elutia Inc

1.090

+0.010+0.93%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively stable. Its valuation is considered undervalued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The company is performing strongly in the stock market, with strong fundamentals and technicals supporting the momentum. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

74 / 175

Overall Ranking

223 / 4720

Industry

Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 2 analysts

Buy

Current Rating

5.500

Target Price

+409.26%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Elutia Inc. is a commercial-stage company, which has developed a portfolio of products using both human and porcine tissue. Its portfolio of products spans the Device Protection, Women’s Health and Cardiovascular markets. These products are primarily sold to healthcare providers or commercial partners. In Device Protection, it sells CanGaroo, a biological envelope, that is indicated for use with implantable electronic devices, including cardiac and neurostimulator devices. In Women’s Health, it has developed both patented and proprietary technologies, culminating in the creation of SimpliDerm, a biological matrix designed to leverage the inherent science of natural healing processes. In Cardiovascular, it sells its specialized porcine small intestine submucosa, which is also the tissue used to make CanGaroo, for use as an intracardiac and vascular patch, as well as for pericardial reconstruction. In addition, its TYKE product is designed for use in the neonatal patient population.

Growing

The company is in a growing phase, with the latest annual income totaling USD 24.38M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 63.99.

Fairly Valued

The company’s latest PE is -3.63, at a medium 3-year percentile range.

Institutional Buying

The latest institutional holdings are 29.13M shares, increasing 15.28% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 1.18M shares of this stock.

Financial Health

Currency: USD Updated: 2025-09-19

The company's current financial score is 7.62, which is lower than the Pharmaceuticals industry's average of 7.84. Its financial status is weak, and its operating efficiency is high. Its latest quarterly revenue reached 6.26M, representing a year-over-year decrease of 0.45%, while its net profit experienced a year-over-year decrease of 65.90%.

Score

Industry at a Glance

Previous score

7.62

Change



Financials

4.94

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.71

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

8.14

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.34

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 1.20, which is lower than the Pharmaceuticals industry's average of 2.06. Its current P/E ratio is -3.59, which is -55.65% below the recent high of -1.59 and -12.96% above the recent low of -4.06.

Score

Industry at a Glance

Previous score

1.20

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 74/175

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

The company’s current earnings forecast score is 8.00, which is higher than the Pharmaceuticals industry's average of 7.78. The average price target for Elutia Inc is 5.50, with a high of 6.00 and a low of 5.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 2 analysts

Buy

Current Rating

5.500

Target Price

+409.26%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

179

Total

Median

Average

Company name

Ratings

Analysts

Elutia Inc

ELUT

Biogen Inc

BIIB

Amgen Inc

AMGN

Vertex Pharmaceuticals Inc

VRTX

Alnylam Pharmaceuticals Inc

ALNY

Eli Lilly and Co

LLY

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

The company’s current price momentum score is 6.09, which is lower than the Pharmaceuticals industry's average of 6.84. Sideways: Currently, the stock price is trading between the resistance level at 2.03 and the support level at 0.61, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.09

Change

0.05

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(1)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.159

Sell

RSI(14)

22.939

Sell

STOCH(KDJ)(9,3,3)

1.930

Oversold

ATR(14)

0.177

Low Volatility

CCI(14)

-86.046

Neutral

Williams %R

97.727

Oversold

TRIX(12,20)

-2.002

Sell

StochRSI(14)

25.404

Buy

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

1.140

Sell

MA10

1.300

Sell

MA20

1.738

Sell

MA50

1.918

Sell

MA100

1.919

Sell

MA200

2.531

Sell

Institutional Confidence

Currency: USD Updated: 2025-09-19

The company’s current institutional recognition score is 7.00, which is higher than the Pharmaceuticals industry's average of 6.26. The latest institutional shareholding proportion is 79.15%, representing a quarter-over-quarter increase of 0.47%. The largest institutional shareholder is The Vanguard, holding a total of 1.18M shares, representing 3.10% of shares outstanding, with 0.53% increase in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Highcape Partners, L.P.

9.52M

+4.62%

Nantahala Capital Management, LLC

3.18M

+11.17%

SilverArc Capital Management, LLC

2.67M

+49.81%

Alyeska Investment Group, L.P.

2.64M

+310.83%

AIGH Capital Management, LLC.

2.16M

+11.84%

Worth Venture Partners, LLC

1.22M

+6.84%

The Vanguard Group, Inc.

Star Investors

988.61K

+5.99%

Birchview Capital, LP

1.19M

-3.08%

Perkins Capital Management, Inc.

1.14M

+32.13%

Knollwood Investment Advisory, LLC

1.03M

+10.70%

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 3.04, which is lower than the Pharmaceuticals industry's average of 4.07. The company's beta value is 0.85. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.